Tags

Type your tag names separated by a space and hit enter

Risk of Gambling Disorder and Impulse Control Disorder With Aripiprazole, Pramipexole, and Ropinirole: A Pharmacoepidemiologic Study.
J Clin Psychopharmacol. 2017 Feb; 37(1):102-104.JC

Abstract

BACKGROUND

Recently, the US Food and Drug Administration issued a warning regarding the potential risk of gambling disorder, but large epidemiologic studies are lacking.

METHODS

We used a large health claims database from the United States and conducted a nested case-control study. Cases were defined as subjects newly diagnosed with gambling disorder or impulse control disorder. For each case, 10 controls were selected and matched to cases by age and follow-up time and calendar time. Adjusted rate ratios were computed with conditional logistic regression.

RESULTS

There are 355 cases of gambling disorder and 3550 controls along with 4341 cases of impulse control disorder and 43,410 corresponding controls. After adjusting for confounders, users of aripiprazole demonstrated an increased risk of pathologic gambling (rate ratio [RR], 5.23; 95% confidence interval [CI], 1.78-15.38) and impulse control disorder (RR, 7.71; 95% CI, 5.81-10.34). The risk was also elevated for pramipexole or ropinirole for both gambling disorder and impulse control disorder (RR, 7.61; 95% CI, 2.75-21.07; RR, 3.28; 95% CI, 2.31-4.66, respectively).

CONCLUSIONS

Our study confirms an association between aripiprazole, pramipexole, or ropinirole and impulse control disorder and gambling disorder.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Etminan M
From the Departments of *Ophthalmology and Visual Sciences, and †Psychology, University of British Columbia, Vancouver, British Columbia, Canada; ‡Department of Neurology, University of Washington, Seattle, WA; §Department of Psychiatry, ∥Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, and ¶Child & Family Research Institute, University of British Columbia; and #Pharmaceutical Outcomes Programme, British Columbia Children's Hospital, Vancouver, British Columbia, Canada.
Sodhi M
No affiliation info available
Samii A
No affiliation info available
Procyshyn RM
No affiliation info available
Guo M
No affiliation info available
Carleton BC
No affiliation info available

MeSH

AdultAntipsychotic AgentsAripiprazoleBenzothiazolesCanadaCase-Control StudiesCohort StudiesDisruptive, Impulse Control, and Conduct DisordersDopamine AgonistsDrug-Related Side Effects and Adverse ReactionsFemaleGamblingHumansIndolesMaleMiddle AgedPramipexole

Pub Type(s)

Journal Article

Language

eng

PubMed ID

27930495

Citation

Etminan, Mahyar, et al. "Risk of Gambling Disorder and Impulse Control Disorder With Aripiprazole, Pramipexole, and Ropinirole: a Pharmacoepidemiologic Study." Journal of Clinical Psychopharmacology, vol. 37, no. 1, 2017, pp. 102-104.
Etminan M, Sodhi M, Samii A, et al. Risk of Gambling Disorder and Impulse Control Disorder With Aripiprazole, Pramipexole, and Ropinirole: A Pharmacoepidemiologic Study. J Clin Psychopharmacol. 2017;37(1):102-104.
Etminan, M., Sodhi, M., Samii, A., Procyshyn, R. M., Guo, M., & Carleton, B. C. (2017). Risk of Gambling Disorder and Impulse Control Disorder With Aripiprazole, Pramipexole, and Ropinirole: A Pharmacoepidemiologic Study. Journal of Clinical Psychopharmacology, 37(1), 102-104. https://doi.org/10.1097/JCP.0000000000000634
Etminan M, et al. Risk of Gambling Disorder and Impulse Control Disorder With Aripiprazole, Pramipexole, and Ropinirole: a Pharmacoepidemiologic Study. J Clin Psychopharmacol. 2017;37(1):102-104. PubMed PMID: 27930495.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Risk of Gambling Disorder and Impulse Control Disorder With Aripiprazole, Pramipexole, and Ropinirole: A Pharmacoepidemiologic Study. AU - Etminan,Mahyar, AU - Sodhi,Mohit, AU - Samii,Ali, AU - Procyshyn,Ric M, AU - Guo,Michael, AU - Carleton,Bruce C, PY - 2016/12/9/pubmed PY - 2017/6/6/medline PY - 2016/12/9/entrez SP - 102 EP - 104 JF - Journal of clinical psychopharmacology JO - J Clin Psychopharmacol VL - 37 IS - 1 N2 - BACKGROUND: Recently, the US Food and Drug Administration issued a warning regarding the potential risk of gambling disorder, but large epidemiologic studies are lacking. METHODS: We used a large health claims database from the United States and conducted a nested case-control study. Cases were defined as subjects newly diagnosed with gambling disorder or impulse control disorder. For each case, 10 controls were selected and matched to cases by age and follow-up time and calendar time. Adjusted rate ratios were computed with conditional logistic regression. RESULTS: There are 355 cases of gambling disorder and 3550 controls along with 4341 cases of impulse control disorder and 43,410 corresponding controls. After adjusting for confounders, users of aripiprazole demonstrated an increased risk of pathologic gambling (rate ratio [RR], 5.23; 95% confidence interval [CI], 1.78-15.38) and impulse control disorder (RR, 7.71; 95% CI, 5.81-10.34). The risk was also elevated for pramipexole or ropinirole for both gambling disorder and impulse control disorder (RR, 7.61; 95% CI, 2.75-21.07; RR, 3.28; 95% CI, 2.31-4.66, respectively). CONCLUSIONS: Our study confirms an association between aripiprazole, pramipexole, or ropinirole and impulse control disorder and gambling disorder. SN - 1533-712X UR - https://www.unboundmedicine.com/medline/citation/27930495/Risk_of_Gambling_Disorder_and_Impulse_Control_Disorder_With_Aripiprazole_Pramipexole_and_Ropinirole:_A_Pharmacoepidemiologic_Study_ L2 - https://doi.org/10.1097/JCP.0000000000000634 DB - PRIME DP - Unbound Medicine ER -